DePuy Synthes Sees Better Execution and Margins in First Quarter
The company grew in the mid-single-digits for 1Q24 but was aided by an unusually robust joint replacement market and one-time...
The company grew in the mid-single-digits for 1Q24 but was aided by an unusually robust joint replacement market and one-time...
The company grew in the low double-digits in 2023 but a strategic review revealed Anika's need to focus on the...
The company grew in the mid-teens in 2023 with significant growth across product segments and most regions....
The company turned in a strong fourth quarter to push 2023 orthopedic sales growth into the low-single-digits....
The company grew in the high teens for 2023, driven by its personalized solutions and strength across geographic regions....
The company grew more than 20% in 2023 as it consistently wins share in its Trauma and Deformity business....
The company grew nearly 80% in 2023, with 104% growth in North America on the strength of CERAMENT G sales...
The company grew in the mid-single-digits on a pro forma basis in 2023 and is focused on leveraging its...
The company grew 19% in 2023 despite contending with supply chain constraints and could growth another 20% in 2024....
The company's MACI revenues grew nearly 25% in 2023 and Vericel expects the launch of MACI Arthro in the third...
As a guest member you get access to more articles and webinars every month.
We’ll send a recovery link to your email.
Return to Homepage